Clinical Trials Sponsored by Revimmune

Total 387 results

MedImmune LLC
AstraZeneca

Completed

Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season (FluMist)

Healthy | Influenza

United States
MedImmune LLC
Amgen

Completed

A Study to Evaluate the Pharmacokinetics of MEDI9929 (AMG 157) in Adolescents With Mild to Moderate Asthma

Asthma

Poland
MedImmune LLC
AstraZeneca

Completed

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season (FluMist)

Healthy | Influenza

United States
MedImmune LLC
AstraZeneca

Completed

A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Poland, Spain, United Kingdom, Denmark, Canada, Germany
AstraZeneca
MedImmune Ltd

Completed

Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis

Ulcerative Colitis

Italy, Poland, United Kingdom, France, Czech Republic, Germany
MedImmune LLC
AstraZeneca

Completed

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

Healthy | Influenza

United States
AstraZeneca
MedImmune LLC

Completed

A Study of MEDI-575 in Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

Japan
AstraZeneca
MedImmune LLC

Completed

A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany, United States, Canada, Russian Federation, Slovakia, Czechia, Bulgaria, Mexico
AstraZeneca
MedImmune LLC

Completed

Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes Melitus

Type 2 Diabetes

Japan
MedImmune LLC
AstraZeneca

Completed

Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season (FluMist)

Healthy | Influenza

United States
MedImmune LLC
PPD

Completed

A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis

Systemic Lupus Erythematosus

United States, Brazil, Canada, Chile
AstraZeneca
MedImmune LLC

Completed

Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects

Cancer | Advanced Solid Malignancies

Japan
MedImmune LLC
AstraZeneca

Terminated

A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Mexico, Peru, South Africa, Canada
MedImmune LLC
AstraZeneca

Completed

An Observational Study to Assess RSV-associated Illness in Adults With COPD and/or CHF (CD-1089)

Respiratory Syncytial Virus, Chronic Obstructive Pulmonary Disease, Congestive Heart Failure

United States, Bulgaria, France, Russian Federation, Canada, Sweden, Germany, Italy, Czech Republic
AstraZeneca
MedImmune LLC

Completed

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI9929 After Single Administration in Healthy Male Japanese Subjects

Healthy

Japan
MedImmune LLC
AstraZeneca

Completed

A Study to Evaluate BioMarkers in Blood Samples in Subjects With Rheumatoid Arthritis

Arthritis

United States
AstraZeneca
MedImmune LLC

Terminated

Study to Assess MEDI -578 in Patients With Osteoarthritis (OA) of the Knee

Pain | Osteoarthritis

United Kingdom
MedImmune LLC
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of MEDI-517P in Healthy Adult Female Volunteers Who Are HPV-16 or HPV-18 DNA Positive

Healthy
Revimmune
University Hospital, Limoges; Amarex Clinical Research

Terminated

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort (ILIAD-7-FR)

COVID-19 | Lymphocytopenia

France
AstraZeneca
Parexel; MedImmune LLC

Recruiting

Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)

Asthma

United States, Puerto Rico
UMC Utrecht
MedImmune LLC

Completed

Advanced Understanding of Staphylococcus Aureus Infections in Europe - Surgical Site Infections (ASPIRE-SSI)

Staphylococcus Aureus | Surgical Wound Infection

United Kingdom, Netherlands, Spain, Czechia, Serbia, Belgium, France, Estonia, Italy, Romania
University Hospital, Limoges
Vanderbilt University Medical Center; Revimmune

Terminated

Immune Reconstitution of Immunosuppressed Sepsis Patients (IRIS-7a)

Severe Sepsis With Septic Shock

France
Advaxis, Inc.
MedImmune LLC

Terminated

A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer

Cervical Cancer | Cancer | Head and Neck Cancer

United States
MedImmune LLC
RTI International

Completed

A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children

Asthma | Immunosuppression | Wheezing

United States
Revimmune
Washington University School of Medicine; Amarex Clinical Research

Terminated

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I ) (ILIAD-7-US-I)

COVID-19 | Lymphocytopenia

United States
Providence Health & Services
MedImmune LLC

Completed

Anti-OX40 Antibody in Head and Neck Cancer Patients

Head and Neck Cancer

United States
MedImmune LLC
Cambridge Antibody Technology

Terminated

A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia

Leukemia, Lymphoma, Chronic Lymphocytic | Leukemia, Prolymphocytic Leukemia, Small | Lymphocytic Lymphoma, Moxetumomab Pasudotox

United States, Poland
Light Chain Bioscience - Novimmune SA

Terminated

Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody (PIANO)

Primary Biliary Cirrhosis

Italy, United Kingdom
Light Chain Bioscience - Novimmune SA

Completed

NI-0801 in Allergic Contact Dermatitis

Allergic Contact Dermatitis
Light Chain Bioscience - Novimmune SA

Completed

NI-0401 in Patients With Acute Renal Allograft Rejection

Acute Renal Transplant Rejection

France
MedImmune LLC
Cambridge Antibody Technology

Completed

A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia

Hairy Cell Leukemia

United States, Poland
Light Chain Bioscience - Novimmune SA

Completed

First in Human Study of NI-0701 in Healthy Volunteers

Healthy Volunteers

United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Revimmune

Withdrawn

Recombinant Human Interleukin-7 (CYT107) to Promote T-Cell Recovery After Cord Blood Transplantation

Umbilical Cord Blood Transplant
Light Chain Bioscience - Novimmune SA

Recruiting

A Study of NI-1801 in Patients With Mesothelin Expressing Solid Cancers

Triple Negative Breast Cancer | Epithelial Ovarian Cancer | Non-squamous Non-small-cell Lung Cancer

Italy, France
Providence Health & Services
MedImmune LLC

Terminated

Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer

Colorectal Neoplasms

United States
Columbia University
AstraZeneca; MedImmune LLC

Terminated

Study to Evaluate the Effects of MEDI6012 on Apolipoprotein B100 Metabolism

Cardiovascular Diseases

United States
National Jewish Health
MedImmune LLC

Unknown

Identification of Epidermal Signatures in Patients With Atopic Dermatitis

Atopic Dermatitis

United States
St. Louis University
MedImmune LLC

Completed

Live Attenuated Influenza Vaccine (LAIV) Versus Trivalent Inactivated Influenza Vaccine in Healthy Adults 18-49 Years

Influenza
Providence Health & Services
MedImmune LLC

Completed

Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer | Cancer of the Prostate

United States
Light Chain Bioscience - Novimmune SA

Completed

Study of an Anti-TLR4 mAb in Rheumatoid Arthritis

Rheumatoid Arthritis

Serbia, Bosnia and Herzegovina, Bulgaria, Georgia, Hungary, Moldova, Republic of, Poland
National Jewish Health
MedImmune LLC

Completed

Identification of Molecular Biomarkers to Stratify Patients With Refractory Asthma

Asthma

United States
Light Chain Bioscience - Novimmune SA

Completed

First in Human Study of an Anti-Toll-like Receptor 4 (TLR4) Monoclonal Antibody (NI-0101) in Adult Healthy Volunteers (NI-0101-01)

Healthy Volunteers

Netherlands
Light Chain Bioscience - Novimmune SA

Completed

NI-0401 in Active Crohn's Disease

Moderate to Severe Crohn's Disease
MedImmune LLC
Cambridge Antibody Technology

Suspended

BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Lymphoma | Leukemia

United States
Epimmune

Unknown

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

United States
Zachariah Michael DeFilipp
Regimmune Corporation

Active, not recruiting

Haplo Peripheral Blood Sct In GVHD Prevention

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | AML | Non Hodgkin Lymphoma | MDS | Myeloproliferative Disorder | GVHD | Graft Vs Host Disease | ALL | CMML | Blood Stem Cell Transplant Failure | MPN | Chemosensitive Hodgkin Lymphoma

United States
M.D. Anderson Cancer Center
MedImmune LLC

Active, not recruiting

Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

Advanced and/or Metastatic Sarcoma

United States
M.D. Anderson Cancer Center
MedImmune LLC

Terminated

Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)

Leukemia

United States
University of Cincinnati
AstraZeneca; MedImmune LLC

Terminated

A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer

Colorectal Cancer

United States
MedImmune LLC
National Cancer Institute (NCI)

Completed

CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia

United States, Canada

Clinical Trials Sponsored by Revimmune

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations